Back to All Events

Cardiovascular and Renal Drugs Advisory Committee

  • IQVIA Solutions Denmark A/S Denmark (map)

The USFDA has scheduled a Cardiovascular and Renal Drugs [CRDAC] Advisory Committee Meeting for September 13, 2023, to discuss a supplemental new drug application (sNDA- 210922-s015), for ONPATTRO (patisiran) lipid complex for injection, submitted by Alnylam Pharmaceuticals, Inc., for the proposed treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults.

Source:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-13-2023-cardiovascular-and-renal-drugs-advisory-committee-meeting-announcement-09132023
Earlier Event: June 28
Endocrinologic Drugs Advisory Committee
Later Event: September 21
Endocrinologic Drugs Advisory Committee